GB9827104D0 - New cancer treatments - Google Patents

New cancer treatments

Info

Publication number
GB9827104D0
GB9827104D0 GBGB9827104.2A GB9827104A GB9827104D0 GB 9827104 D0 GB9827104 D0 GB 9827104D0 GB 9827104 A GB9827104 A GB 9827104A GB 9827104 D0 GB9827104 D0 GB 9827104D0
Authority
GB
United Kingdom
Prior art keywords
derivatives
cells
cancer treatments
whole
portions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9827104.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyvax Ltd
Original Assignee
Onyvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Ltd filed Critical Onyvax Ltd
Priority to GBGB9827104.2A priority Critical patent/GB9827104D0/en
Publication of GB9827104D0 publication Critical patent/GB9827104D0/en
Priority to KR1020017007096A priority patent/KR20010090874A/ko
Priority to EP99959542A priority patent/EP1137422B1/en
Priority to PL348828A priority patent/PL201016B1/pl
Priority to CA2354045A priority patent/CA2354045C/en
Priority to NZ512004A priority patent/NZ512004A/en
Priority to PCT/GB1999/004129 priority patent/WO2000033869A2/en
Priority to DE69927286T priority patent/DE69927286T2/de
Priority to AT99959542T priority patent/ATE304365T1/de
Priority to CZ20012032A priority patent/CZ300499B6/cs
Priority to HU0104568A priority patent/HUP0104568A3/hu
Priority to JP2000586359A priority patent/JP4949554B2/ja
Priority to ES99959542T priority patent/ES2249046T3/es
Priority to IL14329699A priority patent/IL143296A0/xx
Priority to MXPA01005816A priority patent/MXPA01005816A/es
Priority to AU16683/00A priority patent/AU763485B2/en
Priority to US09/857,691 priority patent/US6972128B1/en
Priority to ZA200104164A priority patent/ZA200104164B/en
Priority to IL143296A priority patent/IL143296A/en
Priority to NO20012634A priority patent/NO327044B1/no
Priority to US11/178,415 priority patent/US8034360B2/en
Priority to JP2011223318A priority patent/JP2012021028A/ja
Priority to US13/270,820 priority patent/US20120164099A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
GBGB9827104.2A 1998-12-10 1998-12-10 New cancer treatments Ceased GB9827104D0 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
GBGB9827104.2A GB9827104D0 (en) 1998-12-10 1998-12-10 New cancer treatments
US09/857,691 US6972128B1 (en) 1998-12-10 1999-12-09 Use of human prostrate cell lines in prostate cancer treatment
HU0104568A HUP0104568A3 (en) 1998-12-10 1999-12-09 Human prostatic cell lines for cancer treatment
ES99959542T ES2249046T3 (es) 1998-12-10 1999-12-09 Utilizacion de lineas celulares humanas de la prostata para tratar el cancer de prostata.
PL348828A PL201016B1 (pl) 1998-12-10 1999-12-09 Czynniki immunoterapeutyczne do leczenia raka prostaty, immunogenna kompozycja, kompozycja szczepionki immunoterapeutycznej do leczenia raka prostaty i zastosowanie czynnika immunoterapeutycznego
CA2354045A CA2354045C (en) 1998-12-10 1999-12-09 New cancer treatments
NZ512004A NZ512004A (en) 1998-12-10 1999-12-09 Immunotherapeutic agent for the treatment of prostate cancer comprising 3 prostate cell lines one derived from normal tissue and two from tumor tissue
PCT/GB1999/004129 WO2000033869A2 (en) 1998-12-10 1999-12-09 Use of human prostrate cell lines in cancer treatment
DE69927286T DE69927286T2 (de) 1998-12-10 1999-12-09 Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs
AT99959542T ATE304365T1 (de) 1998-12-10 1999-12-09 Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs
CZ20012032A CZ300499B6 (cs) 1998-12-10 1999-12-09 Použití bunecných linií lidské prostaty k lécbe zhoubného bujení prostaty
KR1020017007096A KR20010090874A (ko) 1998-12-10 1999-12-09 인간 전립선 세포계를 사용한 암치료법
JP2000586359A JP4949554B2 (ja) 1998-12-10 1999-12-09 ガンの新規処置
EP99959542A EP1137422B1 (en) 1998-12-10 1999-12-09 Use of human prostate cell lines for the treatment of prostate cancer
IL14329699A IL143296A0 (en) 1998-12-10 1999-12-09 Use of human prostate cell lines in cancer treatment
MXPA01005816A MXPA01005816A (es) 1998-12-10 1999-12-09 Uso de lineas de celula de prostata humana en el tratamiento de cancer.
AU16683/00A AU763485B2 (en) 1998-12-10 1999-12-09 New cancer treatments
IL143296A IL143296A (en) 1998-12-10 2001-05-22 Factor containing a line of prostate cells, preparations containing it and use in the treatment of prostate cancer
ZA200104164A ZA200104164B (en) 1998-12-10 2001-05-22 Use of human prostrate cell lines in cancer treatment.
NO20012634A NO327044B1 (no) 1998-12-10 2001-05-29 Allogent immunterapeutisk middel, immunogen sammensetning, vaksinesammensetning og anvendelser derav, i forbindelse med behandling av prostatakreft
US11/178,415 US8034360B2 (en) 1998-12-10 2005-07-12 Use of human prostate cell lines in cancer treatment
JP2011223318A JP2012021028A (ja) 1998-12-10 2011-10-07 ガンの新規処置
US13/270,820 US20120164099A1 (en) 1998-12-10 2011-10-11 Use of human prostate cell lines in cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9827104.2A GB9827104D0 (en) 1998-12-10 1998-12-10 New cancer treatments

Publications (1)

Publication Number Publication Date
GB9827104D0 true GB9827104D0 (en) 1999-02-03

Family

ID=10843926

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9827104.2A Ceased GB9827104D0 (en) 1998-12-10 1998-12-10 New cancer treatments

Country Status (19)

Country Link
US (3) US6972128B1 (enExample)
EP (1) EP1137422B1 (enExample)
JP (2) JP4949554B2 (enExample)
KR (1) KR20010090874A (enExample)
AT (1) ATE304365T1 (enExample)
AU (1) AU763485B2 (enExample)
CA (1) CA2354045C (enExample)
CZ (1) CZ300499B6 (enExample)
DE (1) DE69927286T2 (enExample)
ES (1) ES2249046T3 (enExample)
GB (1) GB9827104D0 (enExample)
HU (1) HUP0104568A3 (enExample)
IL (2) IL143296A0 (enExample)
MX (1) MXPA01005816A (enExample)
NO (1) NO327044B1 (enExample)
NZ (1) NZ512004A (enExample)
PL (1) PL201016B1 (enExample)
WO (1) WO2000033869A2 (enExample)
ZA (1) ZA200104164B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
WO2000071156A2 (en) * 1999-05-21 2000-11-30 Onyvax Limited New vaccine formulations-3
US7303911B2 (en) 2000-04-01 2007-12-04 Onyvax Limited Prostate cell lines
US6667479B2 (en) * 2001-06-01 2003-12-23 Raytheon Company Advanced high speed, multi-level uncooled bolometer and method for fabricating same
US20050019336A1 (en) * 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
BRPI0414014A (pt) * 2003-08-26 2006-10-24 Becton Dickinson Co métodos para distribuição intradérmica de agentes terapêuticos
CN101646455A (zh) 2007-02-07 2010-02-10 财团法人阪大微生物病研究会 用于癌症的治疗剂
EP2216041A4 (en) * 2007-11-20 2012-10-24 Nec Corp METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR
AU2009200767A1 (en) * 2008-03-10 2009-09-24 Aristocrat Technologies Australia Pty Limited A gaming system and a method of gaming
EP2376089B1 (en) 2008-11-17 2018-03-14 The Regents of the University of Michigan Cancer vaccine compositions and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3580371B2 (ja) * 1991-10-04 2004-10-20 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ サイトカインおよび抗原を用いた全身の免疫応答の調節
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
WO1995029704A1 (en) * 1994-04-28 1995-11-09 Scott Freeman Cell lines obtained by in vivo migration and by fusion with autoimmune cells
BR9607894A (pt) * 1995-03-17 1999-06-01 Univ California Processo para tratar tumores
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
DE69627527T2 (de) * 1995-12-28 2004-03-04 The Johns Hopkins University School Of Medicine Allogene parakrine cytokine tumor impfstoffe
JP2000506379A (ja) * 1996-02-02 2000-05-30 アメリカ合衆国 ヒト前立腺上皮不死細胞の細胞株およびクローンおよびそれらの研究および前立腺癌治療に対する応用
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
US6972128B1 (en) 2005-12-06
AU763485B2 (en) 2003-07-24
JP2012021028A (ja) 2012-02-02
IL143296A0 (en) 2002-04-21
NZ512004A (en) 2003-08-29
AU1668300A (en) 2000-06-26
US20050249756A1 (en) 2005-11-10
DE69927286D1 (de) 2005-10-20
ATE304365T1 (de) 2005-09-15
CZ20012032A3 (cs) 2001-10-17
JP2002531520A (ja) 2002-09-24
CA2354045C (en) 2012-02-21
ES2249046T3 (es) 2006-03-16
PL201016B1 (pl) 2009-02-27
DE69927286T2 (de) 2006-06-29
EP1137422A2 (en) 2001-10-04
EP1137422B1 (en) 2005-09-14
US8034360B2 (en) 2011-10-11
ZA200104164B (en) 2002-01-24
CZ300499B6 (cs) 2009-06-03
PL348828A1 (en) 2002-06-17
JP4949554B2 (ja) 2012-06-13
CA2354045A1 (en) 2000-06-15
MXPA01005816A (es) 2002-03-27
KR20010090874A (ko) 2001-10-19
WO2000033869A2 (en) 2000-06-15
NO327044B1 (no) 2009-04-06
HUP0104568A3 (en) 2004-05-28
NO20012634L (no) 2001-08-08
IL143296A (en) 2006-06-11
NO20012634D0 (no) 2001-05-29
US20120164099A1 (en) 2012-06-28
WO2000033869A3 (en) 2000-10-12
HUP0104568A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
NO20021830L (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
BR0107705A (pt) Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
GB9827104D0 (en) New cancer treatments
MXPA01010982A (es) Uso de phyllanthus para la estimulacion dirigida al objetivo del sistema inmune.
PT967987E (pt) Composicoes para o tratamento de tumores contendo extractos de cartilagem de tubarao e agentes antineoplasicos
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
WO2006047716A3 (en) Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease
IL117874A0 (en) Pharmaceutical compositions for inhibiting the growth of viruses and cancers
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
MY122216A (en) New vaccine and method of use
AU6083301A (en) Treating eczema and/or psoriasis
AP9801286A0 (en) Therapeutic compounds.
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
TR199802496T2 (xx) Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
ZA200203985B (en) Therapies for tissue damage resulting from ischemia.
IL151165A0 (en) Use of cdp-choline for the prophylactic treatment of cerebral ischemia

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)